Over a very short period of time since their marketing authorisation, COXIBs have become more widely used then traditional NSAIDs. The discussion on the real safety/efficacy of this «new» drug category is however still open. A pilot study has been conducted to assess the feasibility of establishing a prospective cohort of patients exposed to COXIBs, through a network of 22 pharmaceutical units of the NHS each recruiting 10 GPs. Over a period of 6 months, 1962 patients have been recruited and monitored for their clinical course according to a predefined post marketing oriented protocol.
|Translated title of the contribution||Post-marketing surveillance of cyclooxygenase-2 selective inhibitors: A collaborative study with pharmacists and general practitioners|
|Number of pages||6|
|Journal||Giornale Italiano di Farmacia Clinica|
|Publication status||Published - Oct 2002|
ASJC Scopus subject areas
- Pharmacology (medical)